Dyne Therapeutics, Inc.
DYNNasdaq
$23.74
↑ +4.5%Jul 17 close · end-of-day
Price
1Y↑ +154.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$5.5M
Free Cash Flow (TTM)
-$443.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-0.6%
ROIC
-880.3%
Debt / Equity
0.2
Net Cash
$822.8M
Return 1Y
+152.6%
Company profile
Management & directors
- Lucera ErickChief Financial Officer
- Cox JohnCEO & President
- Friedl-Naderer JohannaChief Commercial Officer
- Kerr DouglasChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
DYN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.73↓ -30.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$58.6M | -$150.0M | -$171.0M | -$242.2M | -$343.9M | -$468.2M |
| Net income | -$59.4M | -$149.3M | -$168.10 | -$235.90 | -$317.40 | -$446.20 |
| Diluted EPS | — | -$2.93 | -$3.23 | -$3.95 | -$3.37 | -$3.47 |
| Operating cash flow | -$46.5M | -$119.6M | -$153.6M | -$188.2M | -$292.4M | -$403.2M |
| Free cash flow | -$47.7M | -$123.2M | -$156.7M | -$188.9M | -$294.7M | -$405.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$72.0M | -$105.6M | -$97.2M | -$122.4M | -$115.8M | -$113.9M | -$116.1M | -$125.3M |
| Net income | -$65.1M | -$97.1M | $227.9M | -$115.4M | -$110.9M | -$108.0M | $334.3M | -$120.9M |
| Diluted EPS | -$0.70 | -$0.96 | -$0.90 | -$1.05 | -$0.97 | -$0.76 | -$0.69 | -$0.73 |
| Operating cash flow | -$54.9M | -$74.6M | -$84.3M | -$105.9M | -$94.7M | -$90.8M | -$111.8M | -$144.9M |
| Free cash flow | -$55.7M | -$74.9M | -$85.4M | -$106.9M | -$94.8M | -$91.2M | -$112.3M | -$145.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Coming soonHeadlines for DYN will appear here once the news feed is connected.
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Rhodes Jason P | Sale | 124,379 | $23.17 | $2.9M | filing |
| 2026-07-07 | Rhodes Jason P | Sale | 62,543 | $23.17 | $1.4M | filing |
| 2026-07-07 | Rhodes Jason P | Sale | 49,193 | $23.17 | $1.1M | filing |
| 2026-07-07 | Rhodes Jason P | Sale | 29,587 | $23.62 | $698,844.94 | filing |
| 2026-07-07 | Rhodes Jason P | Sale | 14,844 | $23.62 | $350,615.28 | filing |
| 2026-07-07 | Rhodes Jason P | Sale | 11,665 | $23.62 | $275,527.30 | filing |
| 2026-07-07 | Rhodes Jason P | Sale | 5,000 | $23.61 | $118,050.00 | filing |
| 2026-07-06 | Rhodes Jason P | Sale | 253,039 | $22.79 | $5.8M | filing |
| 2026-07-06 | Rhodes Jason P | Sale | 127,182 | $22.79 | $2.9M | filing |
| 2026-07-06 | Rhodes Jason P | Sale | 100,019 | $22.79 | $2.3M | filing |
| 2026-06-29 | Rhodes Jason P | Sale | 102,969 | $21.14 | $2.2M | filing |
| 2026-06-29 | Rhodes Jason P | Sale | 51,756 | $21.14 | $1.1M | filing |
| 2026-06-29 | Rhodes Jason P | Sale | 40,702 | $21.14 | $860,440.28 | filing |
| 2026-06-26 | Rhodes Jason P | Sale | 162,954 | $21.28 | $3.5M | filing |
| 2026-06-26 | Rhodes Jason P | Sale | 81,903 | $21.28 | $1.7M | filing |
| 2026-06-26 | Rhodes Jason P | Sale | 64,411 | $21.28 | $1.4M | filing |
| 2026-06-25 | Rhodes Jason P | Sale | 12,699 | $21.10 | $267,948.90 | filing |
| 2026-06-25 | Rhodes Jason P | Sale | 6,382 | $21.10 | $134,660.20 | filing |
| 2026-06-25 | Rhodes Jason P | Sale | 5,019 | $21.10 | $105,900.90 | filing |
| 2026-06-25 | Lucera Erick· Chief Financial Officer | Sale | 2,362 | $20.37 | $48,113.94 | filing |
| 2026-06-24 | Rhodes Jason P | Sale | 50,530 | $21.02 | $1.1M | filing |
| 2026-06-24 | Rhodes Jason P | Sale | 25,397 | $21.02 | $533,844.94 | filing |
| 2026-06-24 | Rhodes Jason P | Sale | 19,973 | $21.02 | $419,832.46 | filing |
| 2026-06-23 | Rhodes Jason P | Sale | 77,855 | $21.13 | $1.6M | filing |
| 2026-06-23 | Kersten Dirk | Sale | 71,629 | $21.04 | $1.5M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.